← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksAPUSRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

APUS logoApimeds Pharmaceuticals US, Inc (APUS) Revenue History

Annual and quarterly revenue from 2021 to 2025

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q4 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$0 (0)
Highest Quarter$0 ()

Loading revenue history...

APUS Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$0 (0)

Download Historical Data

5 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

APUS Revenue Analysis (2021–2025)

As of May 8, 2026, Apimeds Pharmaceuticals US, Inc (APUS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.

Looking at the longer-term picture, APUS's historical revenue data shows various trends over time.

When compared to Healthcare sector peers including HALO (+37.6% YoY), ACRS (-58.2% YoY), and NUVB (+1205.5% YoY). Compare APUS vs HALO →

APUS Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
APUS logoAPUSCurrent$0---
HALO logoHALO$1.4B+37.6%+39.2%58.4%
ACRS logoACRS$8M-58.2%+3.8%-975.9%
NUVB logoNUVB$63M+1205.5%--338.7%
PRGO logoPRGO$4.3B-3.6%+0.8%8.1%
Best in groupLowest in group

APUS Historical Revenue Data (2021–2025)

Showing 5 of 5 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$-5,706-$-11,912,562-
2024$0-$0-$-1,275,095-
2023$0-$0-$-747,436-
2022$0-$0-$-639,529-
2021$0-$0-$-1,019,494-

See APUS's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is APUS Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare APUS vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

APUS — Frequently Asked Questions

Quick answers to the most common questions about buying APUS stock.

Is APUS's revenue growth accelerating or slowing?

APUS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is APUS's long-term revenue growth rate?

Apimeds Pharmaceuticals US, Inc's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is APUS's revenue distributed by segment?

APUS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2025 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

APUS Revenue Over Time (2021–2025)